Perioperative Toripalimab/Chemotherapy Combo Improves EFS in Resectable Stage III NSCLC
Perioperative toripalimab plus chemotherapy generated a median event-free survival benefit vs placebo plus chemotherapy in patients with resectable stage III non–small cell lung cancer.
Source: onclive.com